Zobrazeno 1 - 10
of 1 050
pro vyhledávání: '"Ian M Thompson"'
Autor:
Javier Hernandez, Jonathan Gelfond, Martin Goros, Michael A Liss, Yuanyuan Liang, Donna Ankerst, Ian M Thompson, Robin J Leach
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204823 (2018)
BACKGROUND:Finasteride, a 5-alpha reductase inhibitor may have effects on biomarkers such as prostate-specific antigen (PSA) that could be leveraged to improve screening. OBJECTIVE:To determine the predictive characteristics of biomarkers for prostat
Externí odkaz:
https://doaj.org/article/f986d33e6dc8487d81c0710950a5805d
Autor:
Eleanor L Watts, Paul N Appleby, Demetrius Albanes, Amanda Black, June M Chan, Chu Chen, Piera M Cirillo, Barbara A Cohn, Michael B Cook, Jenny L Donovan, Luigi Ferrucci, Cedric F Garland, Graham G Giles, Phyllis J Goodman, Laurel A Habel, Christopher A Haiman, Jeff M P Holly, Robert N Hoover, Rudolf Kaaks, Paul Knekt, Laurence N Kolonel, Tatsuhiko Kubo, Loïc Le Marchand, Tapio Luostarinen, Robert J MacInnis, Hanna O Mäenpää, Satu Männistö, E Jeffrey Metter, Roger L Milne, Abraham M Y Nomura, Steven E Oliver, J Kellogg Parsons, Petra H Peeters, Elizabeth A Platz, Elio Riboli, Fulvio Ricceri, Sabina Rinaldi, Harri Rissanen, Norie Sawada, Catherine A Schaefer, Jeannette M Schenk, Frank Z Stanczyk, Meir Stampfer, Pär Stattin, Ulf-Håkan Stenman, Anne Tjønneland, Antonia Trichopoulou, Ian M Thompson, Shoichiro Tsugane, Lars Vatten, Alice S Whittemore, Regina G Ziegler, Naomi E Allen, Timothy J Key, Ruth C Travis
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0187741 (2017)
IntroductionSex hormones have been implicated in the etiology of a number of diseases. To better understand disease etiology and the mechanisms of disease-risk factor associations, this analysis aimed to investigate the associations of anthropometric
Externí odkaz:
https://doaj.org/article/220b20dddc614ed5b5cb7519e7c7fb1c
Autor:
Okyaz Eminaga, Wei Wei, Sarah J Hawley, Heidi Auman, Lisa F Newcomb, Jeff Simko, Antonio Hurtado-Coll, Dean A Troyer, Peter R Carroll, Martin E Gleave, Daniel W Lin, Peter S Nelson, Ian M Thompson, Lawrence D True, Jesse K McKenney, Ziding Feng, Ladan Fazli, James D Brooks
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0165236 (2016)
The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized pr
Externí odkaz:
https://doaj.org/article/c8acb3ceaf684fd1a6ee51deabd183eb
Autor:
James D Brooks, Wei Wei, Sarah Hawley, Heidi Auman, Lisa Newcomb, Hilary Boyer, Ladan Fazli, Jeff Simko, Antonio Hurtado-Coll, Dean A Troyer, Peter R Carroll, Martin Gleave, Raymond Lance, Daniel W Lin, Peter S Nelson, Ian M Thompson, Lawrence D True, Ziding Feng, Jesse K McKenney
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0132343 (2015)
Distinguishing between patients with early stage, screen detected prostate cancer who must be treated from those that can be safely watched has become a major issue in prostate cancer care. Identification of molecular subtypes of prostate cancer has
Externí odkaz:
https://doaj.org/article/653567b5d56d4ce399262231ead93c8c
Autor:
Cindy H Chau, Douglas K Price, Cathee Till, Phyllis J Goodman, Xiaohong Chen, Robin J Leach, Teresa L Johnson-Pais, Ann W Hsing, Ashraful Hoque, Catherine M Tangen, Lisa Chu, Howard L Parnes, Jeannette M Schenk, Juergen K V Reichardt, Ian M Thompson, William D Figg
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126672 (2015)
OBJECTIVE:In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the risk of prostate cancer by 25%, even though high-grade prostate cancer was more common in the finasteride group. However, it remains to be determined whether finasterid
Externí odkaz:
https://doaj.org/article/45d43f2eaad14865a539568fdd6d3918
Autor:
Roble G Bedolla, Jingjing Gong, Thomas J Prihoda, I-Tien Yeh, Ian M Thompson, Rita Ghosh, Addanki P Kumar
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e44917 (2012)
Prediction of prostate cancer prognosis is challenging and predictive biomarkers of recurrence remain elusive. Although prostate specific antigen (PSA) has high sensitivity (90%) at a PSA level of 4.0 ng/mL, its low specificity leads to many false po
Externí odkaz:
https://doaj.org/article/0b2da0bfc03848b399bf256c57d2485b
Autor:
Alexandra M. Vaiana, Yidong Chen, Jonathan Gelfond, Teresa L. Johnson-Pais, Robin J. Leach, Chethan Ramamurthy, Ian M. Thompson, David A. Morilak
Publikováno v:
Translational Psychiatry, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Advances in prostate cancer treatment have significantly improved survival, but quality of life for survivors remains an under-studied area of research. Androgen deprivation therapy (ADT) is a foundational treatment for advanced prostate can
Externí odkaz:
https://doaj.org/article/8d6495592ceb4518a1303cb15fdd755c
Publikováno v:
Asian Journal of Andrology, Vol 16, Iss 3, Pp 414-414 (2014)
Externí odkaz:
https://doaj.org/article/30efa897e53748ccb79f7bff4c6a6291
Autor:
Lauren Brady, Lisa F. Newcomb, Kehao Zhu, Yingye Zheng, Hilary Boyer, Navonil De Sarkar, Jesse K. McKenney, James D. Brooks, Peter R. Carroll, Atreya Dash, William J. Ellis, Christopher P. Filson, Martin E. Gleave, Michael A. Liss, Frances Martin, Todd M. Morgan, Ian M. Thompson, Andrew A. Wagner, Colin C. Pritchard, Daniel W. Lin, Peter S. Nelson
Publikováno v:
Cancer Medicine, Vol 11, Iss 22, Pp 4332-4340 (2022)
Abstract Background Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline m
Externí odkaz:
https://doaj.org/article/7d57484662bd4dfa80fce8215691bd68
Autor:
Neeraj Agarwal, Catherine M. Tangen, Maha H.A. Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara, Andrea L. Harzstark, Przemyslaw W. Twardowski, Channing J. Paller, Dylan Zylla, Matthew R. Zibelman, Ellis Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson, David I. Quinn
Publikováno v:
Journal of Clinical Oncology. 40:3301-3309
PURPOSE Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-se